Opendata, web and dolomites

InflaPML SIGNED

Promyelocytic leukemia protein (PML) outside the tumor: a new player in the control of inflammation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 InflaPML project word cloud

Explore the words cloud of the InflaPML project. It provides you a very rough idea of what is the project "InflaPML" about.

neuroinflammation    epilepsy    mechanism    er    progression    environment    bases    de    mams    neurological    regulated    post    tumour    site    underlying    inflammasome    reticulum    stroke    prognostic    unexpected    worsening    molecular    shown    axis    diseases    interfaces    components    local    mitochondria    anti    neuroinflammatory    release    prove    goals    unfortunately    neurodegeneration    nervous    existence    hypothesize    outside    penetrant    treat    p2x7    pml    pharmacological    follow    of    brain    therapies    neuronal    illnesses    inflammatory    modulation    damaged    il    therapy    nlrp3    players    cellular    inflammation    acting    compartments    assembly    overcome    pathologies    pathologic    antagonists    clinically    arise    transcriptionally    prognosis    neurodegenerative    modulator    influence    drugs    consistently    sustains    function    elusive       endoplasmic    disease    sterile    link    recruiting    beta    controls    survival    unsuccessful    linked    regulation    persistent    immune   

Project "InflaPML" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI FERRARA 

Organization address
address: VIA ARIOSTO 35
city: FERRARA
postcode: 44121
website: www.unife.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 1˙462˙500 €
 EC max contribution 1˙462˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI FERRARA IT (FERRARA) coordinator 1˙462˙500.00

Map

 Project objective

Local sterile inflammation arise in many pathologic states, including several diseases of the nervous system as brain stroke, neurodegenerative diseases and epilepsy. The persistent and de-regulated inflammatory response sustains these neurological pathologies worsening their prognosis. Different molecular players, as NLRP3 and P2X7 have been shown to contribute to the progression of these illnesses triggering the release of IL-1β and recruiting cellular components of the immune response at the neurodegeneration site. Consistently, brain penetrant P2X7 antagonists are clinically used to treat epilepsy and neurodegenerative diseases, while the pharmacological modulation of IL-1β is still unsuccessful. Unfortunately, the molecular mechanism underlying neuroinflammation and NLRP3 inflammasome assembly remains elusive. Here we propose that different neuroinflammatory diseases can be linked together in a common disease pathway, of which damaged function should be targeted for therapy. Specifically we propose a new mechanism acting on IL-1β regulation: we hypothesize the existence of a new activity of PML outside tumour environment, acting at the endoplasmic reticulum-mitochondria interfaces (MAMs) as modulator of NLRP3 inflammasome. On these bases, I propose a project in which PML activity at MAMs can be the key link of different neuroinflammatory diseases. Our goals are as follow: 1) to demonstrate that PML post-transcriptionally controls NLRP3 activity at the ER/MAMs compartments and thus IL-1β release via P2X7; 2) to prove that IL-1β release have a strong influence on neuronal environment and survival, and might represent a prognostic factor; 3) to develop new drugs targeting PML/NLRP3/P2X7 axis to overcome the unexpected failure of anti-IL-1 therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INFLAPML" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INFLAPML" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More  

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More